Cargando…
Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestima...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576483/ https://www.ncbi.nlm.nih.gov/pubmed/34777580 http://dx.doi.org/10.15420/ecr.2021.22 |
_version_ | 1784595885746814976 |
---|---|
author | Galati, Giuseppe Sabouret, Pierre Germanova, Olga Bhatt, Deepak L |
author_facet | Galati, Giuseppe Sabouret, Pierre Germanova, Olga Bhatt, Deepak L |
author_sort | Galati, Giuseppe |
collection | PubMed |
description | Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure. |
format | Online Article Text |
id | pubmed-8576483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Radcliffe Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85764832021-11-12 Women and Diabetes: Preventing Heart Disease in a New Era of Therapies Galati, Giuseppe Sabouret, Pierre Germanova, Olga Bhatt, Deepak L Eur Cardiol Women and Heart Disease Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure. Radcliffe Cardiology 2021-10-21 /pmc/articles/PMC8576483/ /pubmed/34777580 http://dx.doi.org/10.15420/ecr.2021.22 Text en Copyright © 2021, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
spellingShingle | Women and Heart Disease Galati, Giuseppe Sabouret, Pierre Germanova, Olga Bhatt, Deepak L Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title_full | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title_fullStr | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title_full_unstemmed | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title_short | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
title_sort | women and diabetes: preventing heart disease in a new era of therapies |
topic | Women and Heart Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576483/ https://www.ncbi.nlm.nih.gov/pubmed/34777580 http://dx.doi.org/10.15420/ecr.2021.22 |
work_keys_str_mv | AT galatigiuseppe womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT sabouretpierre womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT germanovaolga womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT bhattdeepakl womenanddiabetespreventingheartdiseaseinaneweraoftherapies |